# A Study to Learn About Berobenatide Given Once Weekly in Adults With Knee Osteoarthritis and Overweight or Obesity With or Without Type 2 Diabetes (VESPER-OA 2)

Study · id `cardio:ct-nct07915609` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07915609](<https://clinicaltrials.gov/study/NCT07915609>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT07915609

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 756 participants.

## Technical summary

Registry record NCT07915609. Randomized; quadruple masking; primary purpose treatment. Start 2026-10-26 (actual); primary completion 2028-08-21 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 756 participants (planned count; ClinicalTrials.gov record NCT07915609, source copy `cardio:ctgov-nct07915609-2026-11-04`, retrieved 2026-11-18)
- Started: 2026-10-26 (actual) (ClinicalTrials.gov record NCT07915609, source copy `cardio:ctgov-nct07915609-2026-11-04`, retrieved 2026-11-18)
- Primary completion: 2028-08-21 (anticipated) (ClinicalTrials.gov record NCT07915609, source copy `cardio:ctgov-nct07915609-2026-11-04`, retrieved 2026-11-18)
- Completion: 2028-10-30 (anticipated) (ClinicalTrials.gov record NCT07915609, source copy `cardio:ctgov-nct07915609-2026-11-04`, retrieved 2026-11-18)
- Countries: United States (ClinicalTrials.gov record NCT07915609, source copy `cardio:ctgov-nct07915609-2026-11-04`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07915609-2026-11-04`, retrieved 2026-11-18)

## The registry's words

- Brief title: A Study to Learn About Berobenatide Given Once Weekly in Adults With Knee Osteoarthritis and Overweight or Obesity With or Without Type 2 Diabetes (VESPER-OA 2)
- Condition: Obesity
- Condition: Overweight and/or Obesity
- Condition: Knee Osteoarthritis
- Condition: Diabetes Melliuts, Type 2
- Intervention (Drug): Berobenatide
- Intervention (Drug): Placebo
- Lead sponsor: Pfizer
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Pfizer (`cardio:org-pfizer`)

## Provenance

Content hash: e5552cb957a2d54bb08f437f06dc0a880c339fda706998c6fae5386ecb156609
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
